Literature DB >> 25530085

Clinical phenotype of APOL1 nephropathy in young relatives of patients with end-stage renal disease.

Elizabeth I Anyaegbu1, Andrey S Shaw, Keith A Hruska, Sanjay Jain.   

Abstract

BACKGROUND: Two coding variants--G1 and G2--in the apolipoprotein L-1 (APOL1) gene are associated with increased incidence of end-stage renal disease (ESRD) in the adult African American population. These variants associate with hypertension-attributed renal disease, focal segmental glomerulosclerosis (FSGS), and HIV-associated nephropathy. We hypothesized that as a genetic disease, APOL1 nephropathy has a pediatric phenotype.
METHODS: We investigated the incidence of APOL1 variants in young African Americans with hypertension or FSGS and a family history of ESRD by conducting a case-control study of 93 pediatric and young adult African Americans with hypertension or FSGS to determine the association with APOL1 risk variants, G1, and G2 using custom-made TaqMan-based allelic discrimination assays.
RESULTS: Forty of the 61 cases (66 %) with a family history of kidney disease had two APOL1 risk variants, significantly higher than the prevalence in controls and the general African American population (p < 0.001); 24 of 29 patients with hypertension-attributed kidney disease had two APOL1 risk variants, while none of nine hypertensive patients without kidney disease had more than one risk allele.
CONCLUSIONS: Although it was a small study cohort, our findings strongly suggest for the first time that two APOL1 risk alleles in young hypertensive African Americans with a family history of ESRD are strongly associated with kidney disease.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25530085      PMCID: PMC4406792          DOI: 10.1007/s00467-014-3031-0

Source DB:  PubMed          Journal:  Pediatr Nephrol        ISSN: 0931-041X            Impact factor:   3.714


  22 in total

1.  Association of trypanolytic ApoL1 variants with kidney disease in African Americans.

Authors:  Giulio Genovese; David J Friedman; Michael D Ross; Laurence Lecordier; Pierrick Uzureau; Barry I Freedman; Donald W Bowden; Carl D Langefeld; Taras K Oleksyk; Andrea L Uscinski Knob; Andrea J Bernhardy; Pamela J Hicks; George W Nelson; Benoit Vanhollebeke; Cheryl A Winkler; Jeffrey B Kopp; Etienne Pays; Martin R Pollak
Journal:  Science       Date:  2010-07-15       Impact factor: 47.728

2.  Identifying Darwinian selection acting on different human APOL1 variants among diverse African populations.

Authors:  Wen-Ya Ko; Prianka Rajan; Felicia Gomez; Laura Scheinfeldt; Ping An; Cheryl A Winkler; Alain Froment; Thomas B Nyambo; Sabah A Omar; Charles Wambebe; Alessia Ranciaro; Jibril B Hirbo; Sarah A Tishkoff
Journal:  Am J Hum Genet       Date:  2013-06-13       Impact factor: 11.025

3.  APOL1 variants associate with increased risk of CKD among African Americans.

Authors:  Meredith C Foster; Josef Coresh; Myriam Fornage; Brad C Astor; Morgan Grams; Nora Franceschini; Eric Boerwinkle; Rulan S Parekh; W H Linda Kao
Journal:  J Am Soc Nephrol       Date:  2013-06-13       Impact factor: 10.121

4.  APOL1 risk variants, race, and progression of chronic kidney disease.

Authors:  Afshin Parsa; W H Linda Kao; Dawei Xie; Brad C Astor; Man Li; Chi-yuan Hsu; Harold I Feldman; Rulan S Parekh; John W Kusek; Tom H Greene; Jeffrey C Fink; Amanda H Anderson; Michael J Choi; Jackson T Wright; James P Lash; Barry I Freedman; Akinlolu Ojo; Cheryl A Winkler; Dominic S Raj; Jeffrey B Kopp; Jiang He; Nancy G Jensvold; Kaixiang Tao; Michael S Lipkowitz; Lawrence J Appel
Journal:  N Engl J Med       Date:  2013-11-09       Impact factor: 91.245

5.  End-stage renal disease in African Americans with lupus nephritis is associated with APOL1.

Authors:  Barry I Freedman; Carl D Langefeld; Kelly K Andringa; Jennifer A Croker; Adrienne H Williams; Neva E Garner; Daniel J Birmingham; Lee A Hebert; Pamela J Hicks; Mark S Segal; Jeffrey C Edberg; Elizabeth E Brown; Graciela S Alarcón; Karen H Costenbader; Mary E Comeau; Lindsey A Criswell; John B Harley; Judith A James; Diane L Kamen; S Sam Lim; Joan T Merrill; Kathy L Sivils; Timothy B Niewold; Neha M Patel; Michelle Petri; Rosalind Ramsey-Goldman; John D Reveille; Jane E Salmon; Betty P Tsao; Keisha L Gibson; Joyce R Byers; Anna K Vinnikova; Janice P Lea; Bruce A Julian; Robert P Kimberly
Journal:  Arthritis Rheumatol       Date:  2014-02       Impact factor: 10.995

6.  Does racial variation in risk factors explain black-white differences in the incidence of hypertensive end-stage renal disease?

Authors:  J C Whittle; P K Whelton; A J Seidler; M J Klag
Journal:  Arch Intern Med       Date:  1991-07

7.  The familial risk of end-stage renal disease in African Americans.

Authors:  B I Freedman; B J Spray; A B Tuttle; V M Buckalew
Journal:  Am J Kidney Dis       Date:  1993-04       Impact factor: 8.860

8.  Kidney disease in the first-degree relatives of African-Americans with hypertensive end-stage renal disease.

Authors:  S Bergman; B O Key; K A Kirk; D G Warnock; S G Rostant
Journal:  Am J Kidney Dis       Date:  1996-03       Impact factor: 8.860

9.  Familial predisposition to nephropathy in African-Americans with non-insulin-dependent diabetes mellitus.

Authors:  B I Freedman; A B Tuttle; B J Spray
Journal:  Am J Kidney Dis       Date:  1995-05       Impact factor: 8.860

10.  Apolipoprotein L1 gene variants associate with hypertension-attributed nephropathy and the rate of kidney function decline in African Americans.

Authors:  Michael S Lipkowitz; Barry I Freedman; Carl D Langefeld; Mary E Comeau; Donald W Bowden; W H Linda Kao; Brad C Astor; Erwin P Bottinger; Sudha K Iyengar; Paul E Klotman; Richard G Freedman; Weijia Zhang; Rulan S Parekh; Michael J Choi; George W Nelson; Cheryl A Winkler; Jeffrey B Kopp
Journal:  Kidney Int       Date:  2012-07-25       Impact factor: 10.612

View more
  12 in total

Review 1.  Genetic risk of APOL1 and kidney disease in children and young adults of African ancestry.

Authors:  Kimberly J Reidy; Rebecca Hjorten; Rulan S Parekh
Journal:  Curr Opin Pediatr       Date:  2018-04       Impact factor: 2.856

Review 2.  The Impact of APOL1 on Chronic Kidney Disease and Hypertension.

Authors:  Todd W Robinson; Barry I Freedman
Journal:  Adv Chronic Kidney Dis       Date:  2019-03       Impact factor: 3.620

3.  Recurrent FSGS Postkidney Transplant: Moving the Needle Forward.

Authors:  Sandra Amaral; Alicia Neu
Journal:  Clin J Am Soc Nephrol       Date:  2016-10-20       Impact factor: 8.237

4.  Racial differences in renal replacement therapy initiation among children with a nonglomerular cause of chronic kidney disease.

Authors:  Derek K Ng; Marva Moxey-Mims; Bradley A Warady; Susan L Furth; Alvaro Muñoz
Journal:  Ann Epidemiol       Date:  2016-10-08       Impact factor: 3.797

Review 5.  APOL1 and kidney cell function.

Authors:  Vinod Kumar; Pravin C Singhal
Journal:  Am J Physiol Renal Physiol       Date:  2019-06-26

Review 6.  Hypertension-attributed nephropathy: what's in a name?

Authors:  Barry I Freedman; Arthur H Cohen
Journal:  Nat Rev Nephrol       Date:  2015-11-10       Impact factor: 28.314

7.  Diagnosis, Education, and Care of Patients with APOL1-Associated Nephropathy: A Delphi Consensus and Systematic Review.

Authors:  Barry I Freedman; Wylie Burke; Jasmin Divers; Lucy Eberhard; Crystal A Gadegbeku; Rasheed Gbadegesin; Michael E Hall; Tiffany Jones-Smith; Richard Knight; Jeffrey B Kopp; Csaba P Kovesdy; Keith C Norris; Opeyemi A Olabisi; Glenda V Roberts; John R Sedor; Erika Blacksher
Journal:  J Am Soc Nephrol       Date:  2021-04-14       Impact factor: 14.978

Review 8.  The CKiD study: overview and summary of findings related to kidney disease progression.

Authors:  Meredith A Atkinson; Derek K Ng; Bradley A Warady; Susan L Furth; Joseph T Flynn
Journal:  Pediatr Nephrol       Date:  2020-02-03       Impact factor: 3.714

9.  APOL1-associated glomerular disease among African-American children: a collaboration of the Chronic Kidney Disease in Children (CKiD) and Nephrotic Syndrome Study Network (NEPTUNE) cohorts.

Authors:  Derek K Ng; Catherine C Robertson; Robert P Woroniecki; Sophie Limou; Christopher E Gillies; Kimberly J Reidy; Cheryl A Winkler; Sangeeta Hingorani; Keisha L Gibson; Rebecca Hjorten; Christine B Sethna; Jeffrey B Kopp; Marva Moxey-Mims; Susan L Furth; Bradley A Warady; Matthias Kretzler; John R Sedor; Frederick J Kaskel; Matthew G Sampson
Journal:  Nephrol Dial Transplant       Date:  2017-06-01       Impact factor: 5.992

10.  Opinions of African American adults about the use of apolipoprotein L1 (ApoL1) genetic testing in living kidney donation and transplantation.

Authors:  Margaret Berrigan; Jasmine Austrie; Aaron Fleishman; Kenneth P Tercyak; Martin R Pollak; Martha Pavlakis; Vinayak Rohan; Prabhakar K Baliga; Liise K Kayler; Thomas H Feeley; James R Rodrigue
Journal:  Am J Transplant       Date:  2020-08-29       Impact factor: 8.086

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.